Summit Therapeutics sets up $380 million at-the-market stock sale program

Summit Therapeutics Inc. disclosed in an 8-K that on July 23, 2026, it entered into a distribution agreement with J.P. Morgan Securities LLC as sales agent, allowing the company to offer and sell shares of its common stock over time with an aggregate offering price of up to $380,000,000.¹

The company stated that it is not obligated to sell any shares under the agreement.¹ Under the terms disclosed, J.P. Morgan will use commercially reasonable efforts, consistent with its normal trading and sales practices, to sell shares based on Summit's instructions, which may include price, time, or size limits or other customary conditions.¹

The filing described the structure as an at-the-market offering, noting that sales may occur through ordinary brokers' transactions, directly on the Nasdaq Global Market or other existing trading markets, through a market maker, in block transactions, or by other legally permitted methods including negotiated transactions.¹ Pricing terms specify that sales may be made at prevailing market prices, at prices related to those prices, or at negotiated prices.¹ Summit will pay a commission of up to 3.0% of the gross sales price per share sold through J.P. Morgan acting as sales agent.¹ The company retains the right to suspend solicitations and offers under the agreement at any time and has no obligation to sell any shares.¹

Any share sales will proceed under Summit's existing registration statement on Form S-3, which the company noted was filed with the SEC on June 9, 2026, under File No. 333-296642, and became automatically effective upon filing.¹ The company also confirmed it submitted an updated offering document with the SEC on the same date the agreement was signed, tied to this new at-the-market sales arrangement.